

SIGN 155: Pharmacological management of migraine

published February 2018

Update report

Date	Update request	Decision	Status	Description
01/08/2024	<p>Incorporate new evidence on the use of oral calcitonin gene-related peptide (CGRP) receptor antagonists.</p> <p>Reconsider the positioning of preventative therapies based on new advice issued by the MHRA on the use of topiramate (June 2024) and Sodium valproate (last updated September 2025)</p>	Update	Published May 2026	<p>New sections added on CGRP receptor antagonists for people with acute migraine (section 3.7) and for the prevention of migraine (section 4.5).</p> <p>Revised advice on the use of ibuprofen during pregnancy (section 3.3).</p> <p>Additional advice on combination therapies for acute migraine (section 3.8).</p> <p>The section on prevention of migraine (section 4) was restructured to reflect changes in prescribing practices and safety advice on the use of sodium valproate and topiramate.</p>
30/09/2023	<p>Strengthen advice on safety of use of topiramate in pregnancy.</p> <p>New advice issued by the MHRA on the use of sodium valproate (Dec 2023).</p>	Update	Published March 2024	<p>Safety advice on use of topiramate, candesartan, flunarazine and CGRP monoclonal antibodies revised.</p> <p>Recommendation for the use of sodium valproate restricted to patients over the age of 55.</p> <p>SMC advice on the CGRP monoclonal antibody, eptinezumb, added to section 8.4.</p>

SIGN 155: Pharmacological management of migraine

published February 2018

Update report

01/12/2021	Incorporate new evidence on the use of CGRP monoclonal antibodies.	Update	Published Sept 2022	New recommendations on the use of CGRP monoclonal antibodies have been added (renumbered section 4.14). SMC advice on CGRP monoclonal antibodies has been added to section 8.4. Annex 4 has been updated with a new version of the MHRA valproate patient card and checklist.
24/04/2018	New advice issued by the MHRA on the use of sodium valproate in women of child bearing potential.	Update	Published June 2018	Minor update to the evidence statement and good practice point on sodium valproate in section 4.6. The new MHRA valproate patient card and checklist have been added to Annex 4.